Navigation Links
Gen-Probe Reports Strong Financial Results for First Quarter 2008, Raises Full-Year Guidance
Date:4/28/2008

million in the prior year period, an increase of 4% that resulted primarily from two factors: increased reimbursement from Novartis of shared development expenses in the companies' blood screening collaboration; and increased reimbursement from 3M related to the companies' collaboration to develop rapid tests for healthcare-associated infections. These increases were partially offset by a reduction in funds received from the U.S. Department of Defense for prostate cancer research.

Royalty and license revenues for the first quarter of 2008 were $18.6 million, compared to $11.5 million in the prior year period. As previously discussed, this increase resulted primarily from $16.4 million of revenue from Bayer, which represents the third and final payment due in connection with the 2006 settlement of the companies' patent infringement litigation. In the prior year period, royalty and license revenues included $10.3 million from Bayer.

Gross margin on product sales in the first quarter of 2008 was 67.8%, compared to 66.5% in the prior year period. This improvement resulted primarily from increased sales of the APTIMA Combo 2 assay and from commercial pricing of the PROCLEIX WNV assay on the TIGRIS system in the United States. These benefits were partially offset by increased instrument sales, as described above.

Research and development (R&D) expenses in the first quarter of 2008 were $23.1 million, compared to $20.3 million in the prior year period, an increase of 14%. This increase resulted primarily from costs associated with key development programs such as the post-marketing studies of the PROCLEIX ULTRIO assay in the United States, the investigational APTIMA(R) human papillomavirus (HPV) assay, and Gen-Probe's fully automated instrument system for low- and mid-volume labs, known as PANTHER.

Marketing and sales expenses in the first quarter of 2008 were $11.9 million, compared to $9.5 million in the prior year period, an increase of 25%
'/>"/>

SOURCE Gen-Probe Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Gen-Probe to Webcast Presentation at Morgan Stanley Global Healthcare Unplugged Conference
2. Gen-Probe to Webcast Presentations at Lehman and Cowen Healthcare Conferences
3. Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007
4. Carl Hull Named President and Chief Operating Officer of Gen-Probe
5. Gen-Probe Announces Webcast of Fourth Quarter and Full Year 2007 Earnings Conference Call
6. Gen-Probe to Webcast Three Upcoming Presentations
7. Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues
8. Gen-Probe to Webcast Presentation at Bank of Americas 37th Annual Investment Conference
9. Simcere Pharmaceutical Group Reports Proposed Private Sale of Ordinary Shares by Existing Shareholder
10. CV Therapeutics Reports 2008 First Quarter Financial Results
11. Caliper Life Sciences Reports West Coast Consolidation of Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... Massachusetts, USA (PRWEB) November 26, 2014 ... more accuracy, additive systems to enable 3D manufacture at ... analyzing road conditions are among finalists in nine categories ... . The awards are sponsored by SPIE, the ... Photonics Media . , Winners will be announced by ...
(Date:11/26/2014)... Dallas, Texas (PRWEB) November 26, 2014 ... Bifluoride Industryā€¯ is a professional and in-depth research ... Ammonium Bifluoride information, like its definition, classification, application, ... overview. This report covers the international market analysis, ... (such as the US, Europe, Asia, China, Japan ...
(Date:11/26/2014)... , Nov. 26, 2014 The announced ... indicate the company is looking to expand in non-healthcare ... sales.  The healthcare market research firm says that  Siemens ... Kalorama Information,s biennial survey of the IVD market , ... any change in its composition would likely affect IVD ...
(Date:11/26/2014)... (PRWEB) November 26, 2014 On January, ... the Baltimore and Washington D.C. science community to the ... The event, sponsored by the Protein Society, will take ... University Center, Room 312. Through discussion, presentations and ... structural importance of proteins, their role in the industry ...
Breaking Biology Technology:Finalists Named for 2015 Prism Awards for Photonics Innovation 2Finalists Named for 2015 Prism Awards for Photonics Innovation 3Finalists Named for 2015 Prism Awards for Photonics Innovation 4Finalists Named for 2015 Prism Awards for Photonics Innovation 5Ammonium Bifluoride Market International Analysis of Manufacturing, Technology & Trends Now at ReportsnReports.com 2Ammonium Bifluoride Market International Analysis of Manufacturing, Technology & Trends Now at ReportsnReports.com 3Kalorama: Sale of Three Siemens Healthcare Units Raises Questions About Firm's IVD Future 2
... ... President, Marketing and Sales, and James Carr Promoted To ... Capacity in China -, - Details to be Presented at Investor Briefing Today at 12 p.m. Eastern ... Time -, SOUTH SAN FRANCISCO, Calif., ...
... Ill. A hybrid device combining force and fluorescence ... made possible the accurate detection of nanometer-scale motion of ... resonance energy transfer and an optical trap, we now ... of a biomolecule at an extremely low applied force, ...
... Oct. 11 Timely Data Resources, Inc.,has recently released ... and Therapy,Review (DTR) reports. Reports are available through subscription ... be purchased,individually at marketresearch.com. These reports offer a quick ... Each overview is,generally 10 to 15 pages in length, ...
Cached Biology Technology:Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM) 2Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM) 3Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM) 4Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM) 5Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM) 6Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM) 7New force-fluorescence device measures motion previously undetectable 2New force-fluorescence device measures motion previously undetectable 3
(Date:11/3/2014)... and preterm birth are linked to increased risk for ... the American College of Rheumatology (ACR) journal, Arthritis ... and pre-term babies were not at greater risk of ... According to the ACR, 27 million Americans over the ... of OA range from mild to severe and include ...
(Date:11/2/2014)... NEW ORLEANS, LA (2 November 2014)—In support of a ... the Bill & Melinda Gates Foundation today announced an ... PATH Malaria Vaccine Initiative (MVI) in building new vaccines ... and help realize the "accelerating to zero" agenda. Such ... providing what could be called an "immunological bed net." ...
(Date:11/2/2014)... and bump into a biologist . . . , While ... sketch, researchers have taken this premise and applied it to ... in the rising oceans of genomic data. , In this ... studies are publishing at a dizzying rate. The challenge is ... the noise (and there is no shortage of noise). , ...
Breaking Biology News(10 mins):Preterm, low birth-weight babies may need new hips in adulthood 2New malaria vaccines to prevent infection and block transmission get a shot in the arm 2New malaria vaccines to prevent infection and block transmission get a shot in the arm 3New malaria vaccines to prevent infection and block transmission get a shot in the arm 4Mutant models 2Mutant models 3Mutant models 4
... the molecular details that show how a viral protein ... them to continuously grow, thereby predisposing people to certain ... of the most common human viruses in the world ... Burkitt's lymphoma as well as the epithelial cell cancer, ...
... aimed at directly controlling the expression of genes by turning ... to drugs for the treatment or cure of many diseases, ... disease starts at the level of malfunctioning gene expression, or ... of pharmacology and biochemistry. "This is an approach that could ...
... cells make their vital connections, embryonic cells move to ... in to destroy pathogenic organisms, and cancer cells metastasize, ... migrations didn't know how cells determined where to go. ... a fragment of a protein that senses chemicals that ...
Cached Biology News:U of T researchers map role of Epstein-Barr virus in cancer 2Gene silencing technique offers new strategy for treating, curing disease 2New understanding of cell movement may yield ways to brake cancer's spread 2